Certara FY2025 EPS Estimate Increased by Leerink Partnrs

Certara, Inc. (NASDAQ:CERT) – Research analysts at Leerink Partnrs upped their FY2025 earnings per share (EPS) estimates for Certara in a note issued to investors on Monday, April 14th. Leerink Partnrs analyst M. Cherny now expects that the company will earn $0.29 per share for the year, up from their prior estimate of $0.27. The consensus estimate for Certara’s current full-year earnings is $0.28 per share.

Several other analysts have also weighed in on CERT. William Blair reiterated a “market perform” rating on shares of Certara in a research report on Thursday, February 27th. TD Cowen started coverage on Certara in a research note on Thursday, February 27th. They issued a “buy” rating and a $16.00 price objective on the stock. Stephens reissued an “overweight” rating and issued a $17.00 target price on shares of Certara in a report on Thursday, February 27th. Robert W. Baird boosted their price target on Certara from $9.00 to $13.00 and gave the company a “neutral” rating in a research note on Friday, April 11th. Finally, KeyCorp upped their price target on Certara from $15.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $15.17.

Certara Trading Up 4.6 %

Shares of Certara stock opened at $14.15 on Thursday. Certara has a 52-week low of $8.64 and a 52-week high of $17.94. The firm has a market capitalization of $2.28 billion, a PE ratio of -70.75, a price-to-earnings-growth ratio of 9.29 and a beta of 1.64. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The company’s fifty day moving average price is $11.62 and its two-hundred day moving average price is $11.44.

Hedge Funds Weigh In On Certara

Several institutional investors have recently bought and sold shares of CERT. Blue Trust Inc. grew its stake in shares of Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company’s stock valued at $56,000 after purchasing an additional 822 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in Certara by 3.6% during the 4th quarter. The Manufacturers Life Insurance Company now owns 23,720 shares of the company’s stock worth $253,000 after buying an additional 823 shares in the last quarter. Wells Fargo & Company MN boosted its position in Certara by 48.4% in the 4th quarter. Wells Fargo & Company MN now owns 3,208 shares of the company’s stock valued at $34,000 after buying an additional 1,047 shares during the last quarter. Bank of Montreal Can increased its stake in shares of Certara by 9.1% in the 4th quarter. Bank of Montreal Can now owns 19,943 shares of the company’s stock valued at $212,000 after buying an additional 1,670 shares during the period. Finally, Versant Capital Management Inc raised its position in shares of Certara by 218.8% during the first quarter. Versant Capital Management Inc now owns 2,719 shares of the company’s stock worth $27,000 after acquiring an additional 1,866 shares during the last quarter. Institutional investors own 73.96% of the company’s stock.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.